Frontier Medicines Corporation has reported preliminary Phase 1 results showing that its investigational KRAS G12C inhibitor FMC-376 achieved confirmed objective responses in 56% of 18 evaluable patients with heavily pretreated KRAS G12C-mutant non-small cell lung cancer. Presented at the European Society for Medical Oncology Congress 2026 in Madrid, the findings included responses in four of nine patients previously treated with KRAS G12C inhibitors, providing early clinical evidence that the company’s dual-state targeting approach may retain activity after exposure to existing medicines.
The results come from the ongoing Phase 1/2 PROSPER trial, which is investigating FMC-376 as a single agent and in combination with pembrolizumab. Unlike approved KRAS G12C inhibitors that primarily target the inactive form of the mutant protein, FMC-376 is designed to inhibit both active and inactive KRAS G12C conformations with comparable potency.
This pharmacological approach is intended to address limitations associated with incomplete pathway suppression and acquired resistance. The early results are relevant because patients whose disease progresses after KRAS-targeted treatment may have limited subsequent options, particularly when they have already received chemotherapy and immunotherapy.
However, the reported 56% response rate comes from a small, selected Phase 1 efficacy population rather than the entire trial. The study has not demonstrated a survival advantage, and no randomised comparison establishes that FMC-376 is more effective or better tolerated than approved KRAS G12C inhibitors. The findings provide a rationale for continued development rather than definitive evidence of a new treatment standard.
What do the Phase 1 PROSPER results reveal about FMC-376’s antitumor activity?
PROSPER is an open-label Phase 1/2 trial evaluating FMC-376 in patients with locally advanced unresectable or metastatic solid tumors carrying the KRAS G12C mutation. The study includes dose escalation, dose optimisation and expansion cohorts, with the objective of assessing safety, pharmacokinetics and preliminary antitumor activity. Its development programme includes both monotherapy and combination treatment approaches.
As of April 30, 2026, 62 patients had entered the study across evaluated doses and regimens. Twenty-nine patients with non-small cell lung cancer received FMC-376 at 500 milligrams twice daily, while the principal efficacy analysis involved 18 response-evaluable patients treated at that dose.
The 18 patients included in the efficacy analysis had previously received chemotherapy and immunotherapy for metastatic disease. They had received a median of three previous lines of systemic treatment, indicating a population with substantial prior therapeutic exposure. Nine patients had also received and experienced progression following treatment with up to two previous KRAS G12C inhibitors targeting the inactive protein state.
Frontier reported confirmed objective responses in 10 of the 18 patients, corresponding to a response rate of 56%. Among the nine patients who had not previously received a KRAS G12C inhibitor, six responded, producing a response rate of approximately 67%. Four of the nine previously treated with an inactive-state KRAS G12C inhibitor responded, corresponding to approximately 44%.
The disease control rate, which includes patients achieving complete response, partial response or stable disease under the applicable assessment criteria, reached 89% in the overall 18-patient group. Disease control was reported in all nine patients without previous KRAS G12C inhibitor exposure and seven of nine previously exposed patients.
These findings suggest that FMC-376 can produce measurable antitumor activity in a heavily pretreated population, including some individuals whose disease had already progressed after targeted treatment. However, the small number of patients prevents reliable estimation of the response expected in a broader population.
The study was not designed to establish the comparative superiority of FMC-376 against an approved KRAS G12C medicine. Its clinical value will depend on whether the observed activity can be reproduced in larger, appropriately controlled patient cohorts.
Why does targeting both active and inactive KRAS G12C matter in lung cancer?
KRAS is a signalling protein involved in regulating cellular growth and survival. It functions through transitions between an active state associated with guanosine triphosphate and an inactive state associated with guanosine diphosphate. These transitions are normally tightly regulated, allowing cells to respond appropriately to growth signals.
The KRAS G12C mutation changes the protein’s regulation and can support abnormal downstream signalling associated with cancer development. In non-small cell lung cancer, the mutation identifies a molecularly defined patient population for which targeted medicines have become available.
Existing approved KRAS G12C inhibitors, including sotorasib and adagrasib, were developed to bind the mutant protein primarily in its inactive state. By interfering with signalling and limiting activation, these medicines can produce antitumor responses in appropriately selected patients. Their introduction represented an important development for an oncogenic target previously considered difficult to inhibit directly.
However, cancer cells can develop resistance through several mechanisms. These may include secondary changes affecting KRAS itself, amplification of the mutant gene, activation of alternative signalling pathways or changes that support continued growth despite pharmacological inhibition.
One theoretical limitation of targeting only the inactive KRAS G12C state is that a proportion of the mutant protein may remain active or transition between conformations in ways that reduce the completeness of inhibition. Drugs designed to target the active state have therefore emerged as an additional development strategy.
FMC-376 attempts to address both conformations through a single small molecule. Frontier describes the medicine as having comparable inhibitory potency against active and inactive KRAS G12C, a property intended to support more comprehensive suppression of the target.
This mechanism could potentially influence the durability of pathway inhibition and reduce opportunities for some forms of adaptive signalling. Nevertheless, inhibiting both protein states does not guarantee that tumors will remain sensitive indefinitely. Alternative resistance pathways and tumor heterogeneity may still limit treatment effectiveness.
What do the responses after previous KRAS G12C inhibitor treatment suggest about acquired resistance?
The most clinically distinctive component of the PROSPER findings involves the nine patients who had previously received a KRAS G12C inhibitor. Four achieved confirmed responses after treatment with FMC-376, suggesting that the investigational medicine retained activity in some cancers despite prior exposure to an inactive-state inhibitor.
This observation is important because progression after targeted treatment does not necessarily eliminate dependence on the original oncogenic pathway. Some tumors may develop resistance mechanisms that alter the effectiveness of a particular drug without completely removing the underlying biological vulnerability.
A subsequent inhibitor with different binding characteristics or broader conformational activity may therefore produce additional responses in selected patients. However, the mechanism responsible for each response requires careful molecular investigation.
Frontier reported that 15 of the 18 patients in the efficacy population had at least one co-alteration associated with resistance to KRAS G12C inhibitors. Nine of the 10 responding patients had such an alteration, suggesting that the drug demonstrated activity in a molecularly challenging group.
Four responders had KRAS G12C amplification, a resistance-associated alteration that can increase the abundance of mutant KRAS protein. Amplification may contribute to persistent signalling despite treatment, making it particularly relevant to a drug intended to inhibit both active and inactive protein states.
These observations strengthen the biological rationale for FMC-376, but they do not prove that dual-state inhibition directly overcame a specific resistance mechanism in each responding patient. A patient with a resistance-associated alteration may also have other biological characteristics influencing treatment sensitivity.
More detailed genomic analyses, including paired tumor samples or circulating tumor DNA measurements before and during treatment, could help establish whether the medicine suppresses resistant tumor populations and how new resistance mechanisms emerge.
The results also need to be interpreted in the context of the small subgroup. Four responses among nine previously treated patients provide an encouraging signal, but a single additional response or nonresponse would substantially alter the percentage estimate. Larger studies will be required to determine whether the apparent activity is reproducible.
How durable were the responses observed in the PROSPER Phase 1 trial?
Frontier reported a median duration of response of 7.5 months among patients who achieved a confirmed response. The observed range extended from 2.7 months or longer to 13.7 months or longer, reflecting ongoing responses and incomplete follow-up for some participants. Six of the 10 responders remained on treatment at the July 14, 2026 update.
Duration of response is an important measurement in advanced lung cancer because a high initial response rate does not necessarily indicate sustained disease control. Some targeted therapies produce substantial tumor regression followed by progression as resistant cancer populations emerge. A durable response can therefore provide useful information about whether treatment activity persists beyond the initial assessment.
The reported median suggests that at least some patients maintained clinical benefit over several months. Nevertheless, the estimate is based on only 10 responders, and several responses remained ongoing at the cutoff. Additional follow-up may change the observed duration of response and provide a clearer understanding of the distribution of early and prolonged benefit.
The company has not disclosed mature median progression-free survival or overall survival results for the 18-patient efficacy population. These outcomes will be necessary to understand the broader clinical relevance of the response findings, particularly because patients who do not achieve an objective response may still experience temporary disease stabilisation.
The distinction between duration of response and progression-free survival is also important. Duration of response is calculated among patients who respond, whereas progression-free survival incorporates the wider treated population and events occurring before an objective response. The two measures cannot be substituted for each other.
Continued follow-up will also help establish whether activity differs between patients previously exposed to KRAS inhibitors and those receiving targeted treatment for the first time. Such information could influence the development of separate treatment strategies for resistant and treatment-naive disease.
Does the FMC-376 safety profile support combining KRAS inhibition with immunotherapy?
One of Frontier’s key development objectives is to determine whether FMC-376 can be combined with pembrolizumab without unacceptable toxicity. Earlier attempts to combine KRAS G12C inhibition with immune checkpoint therapy have encountered challenges, including hepatic adverse events. These concerns are relevant because immunotherapy is an established component of treatment for many patients with advanced non-small cell lung cancer.
At the 500-milligram twice-daily FMC-376 dose, Frontier reported one treatment-related elevation in hepatic transaminase levels, classified as Grade 2. This represented approximately 3% of the treated group. No Grade 3 or 4 gastrointestinal adverse events were reported at that dose.
Across the evaluated monotherapy dose levels, the most frequently reported treatment-related adverse events included increased blood creatine phosphokinase in 39% of patients, nausea in 36%, diarrhea in 16%, vomiting in 16% and fatigue in 15%. Gastrointestinal events were reported as Grade 1 or 2, and the company stated that no treatment-related adverse events resulted in discontinuation during the disclosed monotherapy experience.
These findings provide a preliminary safety signal supporting continued evaluation. However, the frequency of increased creatine phosphokinase warrants attention because this laboratory measure can reflect muscle-related biological effects. Detailed information about the severity, duration and clinical significance of these elevations will help determine their importance.
The trial has also begun evaluating FMC-376 with pembrolizumab. As of September 16, 2026, three patients had received FMC-376 at 200 milligrams twice daily alongside pembrolizumab. Frontier reported no Grade 3 or higher gastrointestinal or hepatic transaminase adverse events and no treatment-related discontinuations among these initial participants.
The three-patient combination experience is far too limited to establish the regimen’s safety. Rare adverse events, delayed toxicity and treatment-related interactions may become apparent only after larger numbers of patients receive prolonged exposure.
The combination also used a lower FMC-376 dose than the 500-milligram twice-daily monotherapy regimen associated with the principal efficacy results. Safety observations from the lower-dose combination therefore cannot be assumed to establish tolerability at higher exposures.
Before the combination can move into later-stage development, investigators will need to identify an appropriate dose, assess hepatic and immune-related adverse events and determine whether both medicines can be administered without compromising treatment intensity.
How does FMC-376 compare with approved KRAS G12C inhibitors and newer investigational medicines?
The KRAS G12C treatment landscape has become more competitive since the introduction of the first approved inhibitors. Amgen’s LUMAKRAS (sotorasib) received United States accelerated approval in May 2021 for previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer. KRAZATI (adagrasib), developed by Mirati Therapeutics and subsequently incorporated into Bristol Myers Squibb’s portfolio, received accelerated approval for a similar lung cancer setting in December 2022.
These medicines established proof that direct KRAS G12C inhibition can produce clinically meaningful antitumor activity. However, acquired resistance, incomplete responses and treatment tolerability remain important development challenges.
Next-generation programmes have pursued several approaches, including molecules with different binding characteristics, enhanced potency and combination strategies involving immune checkpoint inhibitors or other targeted treatments. The development landscape also includes active-state KRAS G12C inhibitors and candidates designed to address adaptive signalling.
FMC-376 is differentiated by its proposed ability to inhibit both active and inactive KRAS G12C conformations with comparable potency. Its early activity after previous targeted treatment provides a rationale for further development, but the mechanism cannot yet be translated into a claim of superior clinical performance.
Frontier described the observed efficacy as having best-in-class potential. Such positioning remains a company assessment rather than a conclusion demonstrated by a head-to-head trial. The 56% response rate from 18 evaluable patients cannot be compared directly with response rates from larger studies involving different populations, prior treatments or follow-up periods.
The same limitation applies to tolerability comparisons. Differences in dose, patient characteristics and adverse-event reporting can make separate trials difficult to compare. A low rate of liver enzyme elevation in an early study does not establish that FMC-376 is safer than other KRAS G12C inhibitors.
A commercially meaningful advantage would require stronger evidence of response durability, activity after resistance and an acceptable safety profile in a clearly defined treatment setting. The most persuasive differentiation would come from appropriately designed comparative studies rather than historical response-rate rankings.
Why is Frontier Medicines exploring FMC-376 in first-line lung cancer treatment?
Frontier’s development programme includes a first-line monotherapy cohort in KRAS G12C-mutant non-small cell lung cancer and a combination strategy involving pembrolizumab. These approaches would move the medicine beyond the previously treated populations in which the initial efficacy results were obtained.
First-line treatment involves different clinical expectations because patients may be eligible for established chemoimmunotherapy regimens or other treatments selected according to biomarkers and clinical characteristics. A new targeted medicine must therefore demonstrate that its efficacy and safety justify use before conventional treatment rather than only after progression.
The combination with pembrolizumab offers a biologically plausible strategy for linking KRAS pathway suppression with immune checkpoint blockade. Targeted treatment may alter tumor biology and immune interactions, while PD-1 inhibition seeks to support antitumor immune activity. However, the magnitude and clinical relevance of any interaction remain uncertain.
The feasibility of this strategy depends partly on tolerability. If combining the medicines leads to frequent liver injury or other severe adverse events, treatment interruptions and dose reductions could limit efficacy. The early FMC-376 safety findings are encouraging but insufficient to resolve this risk.
The first-line monotherapy strategy presents a separate question. Investigators will need to determine whether FMC-376 can provide sufficient disease control without the addition of standard chemotherapy or immunotherapy in patients who have not previously received systemic treatment for advanced disease.
These development pathways may ultimately require different trial designs and comparator regimens. Positive results in a heavily pretreated Phase 1 population cannot establish that either approach is suitable for first-line use.
What role does the Frontier drug discovery platform play in FMC-376 development?
Frontier Medicines is a privately held, clinical-stage biotechnology company headquartered across Boston and South San Francisco. Its drug discovery strategy combines chemoproteomics, covalent chemistry and computational approaches to identify and develop medicines against difficult molecular targets.
The company describes FMC-376 as a product of its proprietary Frontier Platform, which is intended to support the identification of binding sites and the design of small molecules against challenging proteins. The development of a compound targeting both KRAS G12C conformations reflects this emphasis on chemical and structural drug design.
The ability to engage a molecular target in different functional states may create additional therapeutic opportunities, particularly where conventional inhibitors are limited by protein conformation or adaptive signalling. However, successful molecular design does not independently establish clinical efficacy or commercial value.
The PROSPER results provide human evidence that the resulting medicine has antitumor activity in selected patients. This represents an advance beyond preclinical proof of target engagement, but it remains an early clinical demonstration. Further development must establish whether the drug’s design translates into advantages measurable through meaningful clinical outcomes.
Frontier has also pursued additional investigational programmes involving other challenging molecular targets. Its broader research portfolio reflects a strategy of expanding covalent drug discovery beyond one mutation or disease. However, the success of FMC-376 cannot be used to infer that other programmes will achieve comparable results.
The company’s privately held status also affects how its development progress can be assessed commercially. Unlike publicly traded oncology developers, Frontier does not have a continuously quoted share price or publicly available market capitalisation reflecting daily investor reactions to the trial results.
A successful later-stage FMC-376 programme could support future financing, licensing or partnership opportunities, but none of those outcomes can be assumed from the Phase 1 findings. The immediate development priority remains generating more mature clinical evidence.
What evidence must PROSPER produce before FMC-376 can progress toward pivotal testing?
The ongoing Phase 1/2 programme will need to establish a reliable efficacy estimate across larger patient cohorts. The most useful next evidence will include updated objective response rates, progression-free survival, duration of response and safety results at the selected development dose. Separate analyses of patients with and without previous KRAS G12C inhibitor exposure will be important.
The resistance-focused cohort is especially relevant because it could help determine whether FMC-376 provides an option for patients whose disease has progressed after existing targeted treatment. Larger numbers of previously exposed patients will be necessary to establish whether the initial 44% response rate is reproducible and whether the benefit depends on particular molecular resistance mechanisms.
Molecular profiling may also help identify which alterations remain compatible with treatment response. The observation that several responders carried KRAS G12C amplification provides a useful hypothesis, but its predictive value remains unvalidated. Prospective biomarker analyses could clarify whether this subgroup has a consistent treatment advantage.
For the pembrolizumab combination, safety and dose optimisation will be central. The early three-patient findings cannot establish tolerability, particularly for adverse events that may require prolonged observation. The combination must demonstrate sufficient exposure and clinical activity without unacceptable overlapping toxicity.
Subsequent trials would need to define the intended treatment setting and establish the appropriate standard-of-care comparator. A programme targeting post-KRAS inhibitor resistance would face different clinical and regulatory requirements from one seeking first-line approval. The development strategy may therefore become increasingly differentiated as more evidence emerges.
The United States Food and Drug Administration has not approved FMC-376 for any indication. No completed pivotal efficacy trial or marketing application has been announced. The medicine remains investigational, and its ultimate development pathway will depend on results from the continuing PROSPER study.
Can dual-state KRAS G12C inhibition overcome the limits of existing targeted lung cancer treatment?
The October 2026 PROSPER findings offer early support for Frontier Medicines’ central therapeutic hypothesis. FMC-376 demonstrated confirmed responses in 10 of 18 evaluable patients with heavily pretreated KRAS G12C-mutant non-small cell lung cancer, including four patients who had previously received an inactive-state KRAS inhibitor. The response findings, together with preliminary tolerability observations, justify continued investigation.
The most important limitation is that the efficacy population remains small and selected, while the combination safety database is even less mature. No randomised evidence establishes superiority over existing treatment, and the current results do not demonstrate improved overall survival. The apparent ability to produce responses in resistant tumors is encouraging but requires replication.
The programme’s next stage will determine whether dual-state KRAS G12C inhibition provides a durable and clinically meaningful advantage beyond the initial response signal. Longer follow-up, broader molecular characterisation and an appropriately selected treatment dose will be essential.
For Frontier Medicines, the development opportunity extends beyond achieving an attractive early response percentage. The decisive test will be demonstrating that FMC-376 can provide sustained disease control in a clearly defined patient population while maintaining sufficient tolerability for the intended treatment setting. If those requirements are met, the programme could offer a differentiated approach to KRAS G12C-mutant lung cancer, including patients whose disease has progressed after existing targeted medicines.
